Context Therapeutics Inc. (NASDAQ:CNTX) Receives $6.17 Average PT from Analysts
Shares of Context Therapeutics Inc. (NASDAQ:CNTX – Get Free Report) have been given a consensus recommendation of “Buy” by ...
Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025
Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T ...
American Association of Individual Investors2d
Why Context Therapeutics Inc.’s (CNTX) Stock Is Up 13.22%
Context Therapeutics Inc.’s CNTX share price has surged by 13.22%, which has investors questioning if this is right time to ...
Companies Like Context Therapeutics (NASDAQ:CNTX) Are In A Position To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at ...
Context Therapeutics Reports Full Year 2024 Operating and Financial Results
CTIM-76 first patient dosed in January 2025Cash and cash equivalents of $94.4 million as of December 31, 2024Company expects its cash and cash ...
Piper Sandler Sticks to Their Buy Rating for Context Therapeutics (CNTX)
Piper Sandler analyst Joseph Catanzaro maintained a Buy rating on Context Therapeutics (CNTX – Research Report) today and set a price target of ...
Nasdaq7d
Context Therapeutics Inc. Doses First Patient in Phase 1 Trial of CTIM-76 and Reports Strong Financial Position Transitioning into 2025
Context Therapeutics Inc. announced its financial results for the year ending December 31, 2024, highlighting significant developments in its clinical programs and financial stability. The company ...
Morningstar7d
Context Therapeutics Reports Full Year 2024 Operating and Financial Results
PHILADELPHIA, March 20, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging ...